Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions

Experimental Dermatology

Volumn 20, Issue 8, 2011, Pages 685-688

  Frey, Katharina ^a   Fiechter, Michael ^a,b   Schwager, Kathrin ^a   Belloni, Benedetta ^c   Barysch, Marjam J ^c   Neri, Dario ^a   Dummer, Reinhard ^c  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Fibronectin splice variants; Melanoma; Tenascin C splice variants; Therapeutic antibodies; Vascular tumor targeting

Indexed keywords

ANTIBODY; FIBRONECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F16; MONOCLONAL ANTIBODY F8; MONOCLONAL ANTIBODY L19; TENASCIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BASEMENT MEMBRANE; DERMOEPIDERMAL JUNCTION; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; MELANOMA; METASTASIS; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANTIBODIES, NEOPLASM; CASE-CONTROL STUDIES; DERMIS; EPIDERMIS; EXTRACELLULAR MATRIX; FIBRONECTINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MELANOMA; PROTEIN ISOFORMS; SKIN; SKIN NEOPLASMS; TENASCIN;

EID: 79960330443     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2011.01314.x     Document Type: Article

References (50)

1. Carter P J. Nat Rev Immunol 2006: 6: 343-357.
2. Schrama D, Reisfeld R A, Becker J C. Nat Rev Drug Discov 2006: 5: 147-159.
3. Neri D, Bicknell R. Nat Rev 2005: 5: 436-446.
4. Villa A, Trachsel E, Kaspar M et al. Int J Cancer 2008: 122: 2405-2413.
5. Pini A, Viti F, Santucci A et al. J Biol Chem 1998: 273: 21769-21776.
6. Brack S S, Silacci M, Birchler M et al. Clin Cancer Res 2006: 12: 3200-3208.
7. Berndt A, Kollner R, Richter P et al. Histochem Cell Biol 2010: 133: 467-475.
8. Borsi L, Balza E, Bestagno M et al. Int J Cancer 2002: 102: 75-85.
9. Rybak J N, Roesli C, Kaspar M et al. Cancer Res 2007: 67: 10948-10957.
10. Schwager K, Kaspar M, Bootz F et al. Arthritis Res Ther 2009: 11: R142.
11. Borsi L, Balza E, Gaggero B et al. J Biol Chem 1995: 270: 6243-6245.
12. Zardi L, Carnemolla B, Siri A et al. EMBO J 1987: 6: 2337-2342.
13. Balza E, Borsi L, Allemanni G et al. FEBS Lett 1988: 228: 42-44.
14. Borsi L, Castellani P, Risso A M et al. FEBS Lett 1990: 261: 175-178.
15. Borsi L, Allemanni G, Gaggero B et al. Int J Cancer 1996: 66: 632-635.
16. Zhang G Y, Li X, Yi C G et al. Exp Dermatol 2009: 18: 947-953.
17. Astrof S, Crowley D, Hynes R O. Dev Biol 2007: 311: 11-24.
18. White E S, Baralle F E, Muro A F. J Pathol 2008: 216: 1-14.
19. Mackie E J, Tucker R P. J Cell Sci 1999: 112 (Pt 22): 3847-3853.
20. Weide B, Derhovanessian E, Pflugfelder A et al. Cancer 2010: 116: 4139-4146.
21. Weide B, Eigentler T K, Pflugfelder A et al. Cancer Immunol Immunother 2011: 60: 487-493.
22. Silacci M, Brack S, Schirru G et al. Proteomics 2005: 5: 2340-2350.
23. Pedretti M, Soltermann A, Arni S et al. Lung Cancer 2009: 64: 28-33.
24. Schliemann C, Wiedmer A, Pedretti M et al. Leuk Res 2009: 33: 1718-1722.
25. Natali P G, Nicotra M R, Bigotti A et al. Int J Cancer 1991: 47: 811-816.
26. Chiquet-Ehrismann R, Chiquet M. J Pathol 2003: 200: 488-499.
27. Kaspar M, Zardi L, Neri D. Int J Cancer 2006: 118: 1331-1339.
28. Kaczmarek J, Castellani P, Nicolo G et al. Int J Cancer 1994: 59: 11-16.
29. Tuominen H, Kallioinen M. J Cutan Pathol 1994: 21: 424-429.
30. Van Duinen C M, Fleuren G J, Bruijn J A. Histopathology 1994: 24: 33-40.
31. Natali P G, Nicotra M R, Di Filippo F et al. Br J Cancer 1995: 71: 1243-1247.
32. Latijnhouwers M A, de Jongh G J, Bergers M et al. Arch Dermatol Res 2000: 292: 446-454.
33. Tarli L, Balza E, Viti F et al. Blood 1999: 94: 192-198.
34. Sauer S, Erba P A, Petrini M et al. Blood 2009: 113: 2265-2274.
35. Birchler M T, Thuerl C, Schmid D et al. Otolaryngol Head Neck Surg 2007: 136: 543-548.
36. Tijink B M, Perk L R, Budde M et al. Eur J Nucl Med Mol Imaging 2009: 36: 1235-1244.
37. Tijink B M, Neri D, Leemans C R et al. J Nucl Med 2006: 47: 1127-1135.
38. Riva P, Franceschi G, Frattarelli M et al. Acta Oncol 1999: 38: 351-359.
39. Paganelli G, Bartolomei M, Grana C et al. Neurol Res 2006: 28: 518-522.
40. Zalutsky M R, Reardon D A, Akabani G et al. J Nucl Med 2008: 49: 30-38.
41. Castellani P, Borsi L, Carnemolla B et al. Am J Pathol 2002: 161: 1695-1700.
42. Agarwala S S. Expert Rev Anticancer Ther 2009: 9: 587-595.
43. Fang L, Lonsdorf A S, Hwang S T. J Invest Dermatol 2008: 128: 2596-2605.
44. Kirkwood J M, Tarhini A A, Panelli M C et al. J Clin Oncol 2008: 26: 3445-3455.
45. Johannsen M, Spitaleri G, Curigliano G et al. Eur J Cancer 2010: 46: 2926-2935.
46. Garbe C, Romanini A, Spitaleri G et al. ASCO Meeting Abstracts 2009: 27: 9064.
47. Weide B, Eigentler T K, Romanini A et al. ASCO Meeting Abstracts 2010: 28: 8555.
48. Garbe C. Treatment of melanoma: state of the art. In: AOS Asian Oncology Summit. Bali, Indonesia, 2010.
49. Frey K, Schliemann C, Schwager K et al. J Urol 2010: 184: 2540-2548.
50. van Dongen G A, Visser G W, Lub-de Hooge M N et al. Oncologist 2007: 12: 1379-1389.